Download full release - University Hospitals Newsroom

Date
Contacts
Phone
December 12, 2013
Alicia Reale
216-844-5158
[email protected]
News Release
Department of Marketing and
Communications
11100 Euclid Avenue
Cleveland, OH 44106
New Research Uses Deep Sequencing of Breast Cancer Tumors to Predict Clinical
Outcomes in Patients After Single Dose of Therapy
Data presented at the 2013 San Antonio Breast Cancer Symposium
CLEVELAND: New research from University Hospitals (UH) Case Medical Center Seidman
Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve
University examined how changes in the genetic composition of breast cancer tumors after brief
exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in
patients.
Results showed that through deep genome sequencing, a reduction in the most commonly
mutated genes in breast cancer could be observed after just one dose of preoperative therapy.
Deep sequencing is a process that involves sequencing the same region multiple times to identify
mutations within tumors that have an importance in cancer evolution. These new findings were
presented during the 2013 San Antonio Breast Cancer Symposium.
“Genomics is the new frontier of cancer research, and this study shows that we may be able to
accurately determine what treatment methods will and will not be effective for individual
patients after just one dose of medicine,” said Lyndsay Harris, MD, study investigator and
Director, Breast Cancer Program, UH Seidman Cancer Center and Professor of Medicine at Case
Western Reserve University School of Medicine. “The ability to understand potential clinical
outcomes for patients earlier in the treatment process would provide physicians with better
opportunity to personalize patients’ medicines according to their own tumor responses.”
More than 209,000 patients in the U.S. are diagnosed with breast cancer each year. The
anticipated outcome of studying the genetic makeup of breast cancer patients is to determine who
will benefit most from certain drug therapies and to use that information to create a personalized
treatment plan for each patient involved. Dr. Harris and team are currently integrating whole
genome profiles with deep sequencing data as they spearhead a new study at UH Seidman
Cancer Center to validate these initial findings presented in San Antonio.
Dr. Harris’ co-presenters are: Nicole Williams, Vinay Varadan, Kristy Miskimen, Aditi
Vadodkar, Debora Poruban,, Simone Edelheit, Hannah Gilmore, Steve Maximuk, Natalie
Sinclair, Kimberly Lezon-Geyda, Maysa Abu-Khalaf, William Sikov, University Hospitals Case
Medical Center/Case Western Reserve University, Cleveland, OH; Yale University School of
Medicine; Yale Comprehensive Cancer Center, New Haven, CT; Warren Alpert Medical School
of Brown, Providence, RI.
About the Studies
P1-08-16: Poster Session 1: Prognosis and Response Prediction: Response Predictive
Factors
Deep sequencing of breast tumor biopsies reveals an association between pathologic complete
response (pCR) and reduction of TP53 clonal abundance upon brief exposure to therapy
Wednesday 12/11, 5:00 PM -7:00 PM
Investigators evaluated 120 Stage IIA to IIIB breast cancer patients and compared a first biopsy
after brief exposure to either biologic or chemotherapy treatment with a second biopsy taken
after surgery. Researchers utilized deep genomic sequencing to quantify the abundance of clonal
mutations in breast core biopsies, assess changes in these mutations after brief exposure to a
targeted therapy and then evaluate the corresponding change in abundance of these mutations
after exposure. This process of quantifying and monitoring clonal mutations between initial
therapy exposure and surgery allowed researchers to determine how changes in the abundance of
these mutations related to a patient’s response to preoperative therapy. Through this analysis,
investigators determined that clonal abundance upon brief exposure to therapy may be associated
with clinical outcomes.
###
About University Hospitals
University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and
primary care physicians. At the core of our health system is University Hospitals Case Medical Center. The primary
affiliate of Case Western Reserve University School of Medicine, UH Case Medical Center is home to some of the
most prestigious clinical and clinical research centers of excellence in the nation and the world, including cancer,
pediatrics, women's health, orthopaedics and spine, radiology and radiation oncology, neurosurgery and
neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus
includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top children's
hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman
Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. For more information, go to
UHhospitals.org.